Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PYC Therapeutics Limited ( (AU:PYC) ) has shared an update.
PYC Therapeutics has proposed, subject to shareholder approval, the issuance of 1.5 million unlisted options to managing director Dr Rohan Hockings under its Long Term Incentive Plan, with a four-year expiry, growth-oriented exercise price of $2.52 and staged vesting over 12 and 24 months. The board says the move follows a broader review of retention incentives for key personnel driving the company’s RNA therapy pipeline and is designed to align Hockings’ remuneration with shareholder value creation and the rigorous governance and execution standards required as PYC advances its precision medicine programs.
The most recent analyst rating on (AU:PYC) stock is a Buy with a A$2.85 price target. To see the full list of analyst forecasts on PYC Therapeutics Limited stock, see the AU:PYC Stock Forecast page.
More about PYC Therapeutics Limited
PYC Therapeutics Limited is a clinical-stage biotechnology company focused on developing a new generation of RNA therapies for patients with monogenic genetic diseases that currently lack effective treatment options. Leveraging a proprietary drug delivery platform to enhance the potency of precision medicines within the RNA therapeutic class, the ASX-listed company targets indications with a relatively high likelihood of clinical development success and is positioned within the rapidly growing RNA therapeutics market.
Average Trading Volume: 429,916
Technical Sentiment Signal: Buy
Current Market Cap: A$979.9M
Find detailed analytics on PYC stock on TipRanks’ Stock Analysis page.